CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition.
Liu X, Lu Y, Huang J, Xing Y, Dai H, Zhu L, Li S, Feng J, Zhou B, Li J, Xia Q, Li J, Huang M, Gu Y, Su S.
Liu X, et al. Among authors: huang m, huang j.
Cancer Cell. 2022 Nov 14;40(11):1341-1357.e13. doi: 10.1016/j.ccell.2022.10.015.
Cancer Cell. 2022.
PMID: 36379207
Free article.